. 2022 Oct 14;5(1):15–23. doi: 10.1016/j.cjco.2022.10.004

Table 3.

Observed anticoagulation at 1 month following cohort entry vs guideline-expected proportions of oral anticoagulation

	Anticoagulation, n (%)		P
	Observed	Expected dispensation according to 2016 CCS AF guidelines	P
Pre-guidelines period, 2012–2015 (n = 1812)^∗	983 (54.3)	1601 (88.4)	< 0.01
Post-guidelines period, 2016–2017 (n = 1289)^†	730 (56.6)	1186 (89.7)	< 0.01

AF, atrial fibrillation; CCS, Canadian Cardiovascular Society.

^∗

Among the 1914 patients in subcohort 2012–2015, a total of 1812 had available data concerning the medication exposure at 1 month following cohort entry.

^†

Among the 1352 patients in subcohort 2016–2017, a total of 1289 had available data concerning the medication exposure at 1 month following cohort entry.